RECRUITINGOBSERVATIONAL
Performance of Inherited Risk Assessment for Predicting Prostate Cancer From Prostate Biopsy
Observational and Prospective Study on the Performance of Inherited Risk Assessment for Predicting Prostate Cancer From Prostate Biopsy (GenBx)
About This Trial
Condition: Prostate cancer Intervention: Biopsy and inherited risk assessment
Who May Be Eligible (Plain English)
Who May Qualify:
- Consecutive patients undergoing prostate biopsy for detection of prostate cancer
- Aged 40 to 69 years
- Four ethnicity groups (Caucasian, African Americans, East Asians, Latinos)
- PSA between 2.5-10 ng/mL
Who Should NOT Join This Trial:
- Previous diagnosis of prostate cancer.
- Ethnicity outside the inclusion criterion (including mixed ethnicity).
- Any prior PSA test result outside the range of inclusion criterion.
Always talk to your doctor about whether this trial is right for you.
Original Eligibility Criteria
View original clinical language
Inclusion Criteria:
* Consecutive patients undergoing prostate biopsy for detection of prostate cancer
* Aged 40 to 69 years
* Four ethnicity groups (Caucasian, African Americans, East Asians, Latinos)
* PSA between 2.5-10 ng/mL
Exclusion Criteria:
* Previous diagnosis of prostate cancer.
* Ethnicity outside the inclusion criterion (including mixed ethnicity).
* Any prior PSA test result outside the range of inclusion criterion.
Treatments Being Tested
GENETIC
Genetic Assessment
The trial is to observe whether inherited risk, including rare pathogenic mutations (RPMs) in several major genes and SNPs-based genetic risk scores (GRS), is correlated with prostate cancer detection rate from diagnostic prostate biopsy.
Locations (1)
NorthShore University HealthSystem
Evanston, Illinois, United States